GleamWall
中文EN

IDXG INTERPACE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—

Margins

Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%

Returns

ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x

Leverage & solvency

Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.37M$9.13M$9.03M$9.22M$8.76M$9.23M$11.52M$12.32M
Cost of revenue$3.19M$3.48M$3.13M$3.18M$3.32M$3.96M$4.14M$3.40M
Gross profit$7.18M$5.65M$5.90M$6.04M$5.44M$5.28M$7.37M$8.92M
R&D expense$160,000$149,000$153,000$142,000$150,000$173,000$177,000$193,000
SG&A expense$6.72M$2.98M$2.45M$2.21M$2.06M$2.66M$2.55M$2.57M
Operating income-$2.40M$321,000$1.12M$1.58M$1.15M-$468,000$1.83M$3.07M
Interest expense————$30,000$49,000$78,000—
Pretax income-$2.38M$330,000$1.13M$1.53M$1.00M-$533,000$1.77M$2.87M
Income tax-$884,000$64,000$302,000-$21.22M-$11,000$0$18,000-$8,000
Net income-$1.61M$158,000$721,000$22.66M$911,000-$640,000$1.65M$2.89M
EBITDA-$2.26M$448,000$1.24M$1.70M$1.26M-$367,000$1.92M$3.17M
EPS (basic)-0.280.010.03—1.03-0.140.37—
EPS (diluted)-0.280.010.03—0.16-0.140.06—
Weighted avg. shares (diluted)5.71M27.71M27.71M—5.54M4.42M27.70M—
Balance sheet
Cash & equivalents$2.93M$2.69M$2.65M$2.50M$1.42M$502,000$1.20M$1.46M
Receivables$7.60M$6.31M$5.92M$5.65M$5.97M$7.23M$8.77M$8.54M
Inventory$1.27M$1.08M$961,000$1.11M$1.10M$973,000$1.21M$1.21M
Current assets$13.29M$10.97M$9.96M$9.90M$9.13M$9.50M$11.65M$11.77M
PP&E, net$1.45M$1.62M$1.31M$1.42M$1.54M$1.37M$1.28M$1.36M
Total assets$37.47M$34.55M$33.41M$33.84M$12.04M$12.34M$14.49M$14.79M
Current liabilities$6.44M$4.95M$3.96M$5.10M$5.95M$7.15M$8.68M$10.62M
Total liabilities$12.78M$11.30M$10.33M$11.47M$12.33M$13.55M$15.08M$17.01M
Shareholders' equity$24.69M$23.24M$23.08M$22.36M-$298,000-$1.21M-$582,000-$2.22M
Shares outstanding5.90M27.70M27.70M885,7084.43M4.42M4.42M4.41M
Cash flow statement
Operating cash flow$970,000$98,000$283,000$2.14M$1.94M$520,000$1.24M$1.18M
Capital expenditure$376,000$57,000$141,000$38,000$117,000——$129,000
Free cash flow$594,000$41,000$142,000$2.10M$1.82M——$1.05M
Investing cash flow-$369,000-$57,000-$141,000-$38,000-$117,000——-$129,000
Financing cash flow———-$1.02M-$900,000-$1.01M-$1.50M-$1.71M
Depreciation & amortization$141,000$127,000$118,000$118,000$111,000$101,000$95,000$95,000
Stock-based compensation$3.99M$4,000$4,000$4,000$7,000$9,000$15,000$73,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.